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OBJECTIVE—Predictors of gestational diabetes mellitus
(GDM) have been widely studied, but few studies have consid-
ered multiple measures. Our objective was to integrate several
potential GDM predictors with consideration to both simple and
novel measures and to determine the extent to which GDM can
be predicted in the ﬁrst trimester.
RESEARCH DESIGN AND METHODS—We identiﬁed ﬁrst-
trimester maternal samples from 124 women who developed
GDM and 248 control subjects who did not. We gathered data on
age, BMI, parity, race, smoking, prior GDM, family history of
diabetes, and blood pressure. Using retrieved samples, we mea-
sured routine (lipids, high-sensitivity C-reactive protein, and
-glutamyltransferase) and novel (adiponectin, E-selectin, and
tissue plasminogen activator [t-PA]) parameters. We determined
independent predictors from stepwise regression analyses, cal-
culated areas under the receiver-operating characteristic curves
(AUC-ROC), and integrated discrimination improvement (IDI)
for relevant models.
RESULTS—Compared with control subjects, women who sub-
sequently developed GDM were older, had higher BMIs, were
more likely to be of Asian origin, had a history of GDM or family
history of type 2 diabetes, and had higher systolic blood pressure
(P  0.05 for all). With regard biochemical measures, stepwise
analyses identiﬁed only elevated t-PA and low HDL cholesterol
levels as signiﬁcant (P  0.015) independent predictors of GDM
beyond simple non–laboratory-based maternal measures. Their
inclusion improved the AUC-ROC from 0.824 to 0.861 and IDI by
0.052 (0.017–0.115).
CONCLUSIONS—GDM can be usefully estimated from a mix of
simple questions with potential for further improvement by
speciﬁc blood measures (lipids and t-PA). Diabetes 59:3017–
3022, 2010
T
here is growing interest in our ability to predict
which women will develop gestational diabetes
mellitus (GDM), given that there is now emerg-
ing evidence that lifestyle changes cannot only
lessen diabetes risk in nonpregnant individuals but also
risks in women with GDM. Currently, the traditional
method of GDM screening is based on maternal history,
which provides a detection rate of 60% for a 40%
false-positive rate (National Institute for Health and Clin-
ical Excellence, available at http://www.nice.org.uk/
CG63). In contrast to the wealth of work for type 2
diabetes, as recently reviewed (1), the literature on early
ﬁrst-trimester biomarkers predictive of GDM are less
mature and considerably further from clinical utility.
Moreover, most relevant studies on this topic (2–4) gen-
erally included 1) 50 incident cases with various num-
bers of control subjects, 2) tended to focus on one or two
biomarkers in isolation rather than capture several poten-
tial markers, and 3) generally did not examine predictive
ability using metrics such the receiver-operating charac-
teristic curve (ROC) analyses or integrated discrimination
improvement (IDI) analyses.
We sought to advance the ﬁeld by examining the pre-
dictive ability of routinely booking maternal demographic
and clinical variables and, importantly, a range of com-
monly available biochemical tests in most laboratories
(lipids, high-sensitivity C-reactive protein [CRP], and -glu-
tamyltransferase [GGT]) and key nonroutine tests derived
by organs relevant to diabetes (adipose tissue, liver, and
endothelium). Among the fat-derived markers, adiponectin
is strongly predictive of type 2 diabetes, as documented by
a recent meta-analysis (5). Similarly, recent meta-analyses
report hepatic-derived CRP (6) and GGT (7) to be associ-
ated with risk for type 2 diabetes, although CRP’s associ-
ation with type 2 diabetes may not be independent of
central obesity. Finally, we have shown tissue plasmino-
gen activator (t-PA) to be a strong independent predictor
of diabetes, independent even of insulin resistance (8),
whereas E-selectin is the strongest adhesion molecule
predictive of diabetes (9). Overall, therefore, we captured
key measures reﬂecting perturbances in a range of differ-
ent pathways (lipids, inﬂammation, liver fat, adipocytes,
and vascular function) pertinent to the pathogenesis of
diabetes.
RESEARCH DESIGN AND METHODS
We performed a nested case-control study using ﬁrst-trimester samples that
were stored as part of our large prospective observational ongoing study
aimed at identifying ﬁrst-trimester predictors of adverse pregnancy outcomes.
The study involved women attending for their routine hospital visit at King’s
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gestation, all women have an ultrasound scan to conﬁrm gestational age,
diagnose any major fetal abnormalities, and measure fetal nuchal translu-
cency thickness, which together with maternal free -chorionic gonadotro-
phin and pregnancy-associated plasma protein A, is used for screening for
chromosomal abnormalities. Patients were asked to complete a questionnaire
on maternal age, address, and postcode to assess area-based socioeconomic
status, racial group, cigarette smoking during pregnancy, method of concep-
tion, parity, and obstetric and family history of diabetes. The maternal weight
and height were measured, and BMI was calculated as weight in kilograms
divided by the square of height in meters. Peripheral maternal blood pressure
was measured using an ambulatory blood pressure monitor (3BTO-A2;
Microlife Medical, Taipei, Taiwan), which has been validated in pregnancy.
Maternal blood was taken and stored at 80°C for future biochemical
analyses.
All women underwent routine second-trimester screening for GDM (24–28
weeks’ gestation) according to the two-step risk factor screening procedure
(http://www.nice.org.uk/CG63). A 75-g load, 2-h oral glucose tolerance test
(OGTT) was performed based on maternal risk factors as deﬁned by the NICE
(BMI 30 kg/m
2, previous GDM, ﬁrst-degree relative with diabetes, previous
large-for-gestational-age infant) or in those women with no risk factors if an
initial random plasma glucose was 6.7 mmol/l. Gestational diabetes was
deﬁned by one abnormal plasma glucose value following the OGTT, with
normal values of 7 and 7.8 mmol/l for fasting and 2-h postprandial values,
respectively, based on World Health Organization criteria. If women with
normal random blood glucose subsequently developed apparent risk factors
such as polyhydramnios, a large-for-gestational-age fetus, or persistent glu-
cosuria, then an OGTT was performed (requiring, in some cases, a second
OGTT). The values of the OGTT and A1C levels, whenever available, were
obtained. Furthermore, details including gestational age at delivery, mode of
delivery, birth weight, and sex of the neonate have also been retrieved.
Women with preexisting diabetes and twin pregnancies were excluded. All
women had phenotypically normal neonates. All women had given written
informed ethical consent and the project had been approved by the local
research ethics committee.
We had aimed to identify stored samples (all 3 years old) from at least
100 women with subsequent GDM, veriﬁed with an OGTT, and 200 women
who did not develop GDM. This would provide 80% power at an  of 0.05 to
detect a standardized difference of 0.3 for any variable or 96% power at an 
of 0.01 to detect a standardized difference of 0.5. For each woman who
developed GDM, two control subjects were selected who were matched
according to the date of the ultrasound scan and consequent storage time of
the samples.
Biochemical assays. Lipids (cholesterol, LDL cholesterol, HDL cholesterol,
nonfasting triglycerides, CRP, and GGT) were measured by routine automated
methods in an accredited laboratory. The CRP method is sensitive to a value
of 0.2 mg/l, and all methods have coefﬁcients of variation of 4%. Baseline
adiponectin, E-selectin, and t-PA were measured by enzyme-linked immu-
nosorbent assay (R&D Systems, Abingdon, U.K.) on previously unthawed
serum samples stored at 80°C. The methods had interassay coefﬁcients of
variation 7%. Samples were processed by technicians blinded to the identity
of samples.
Statistics. Categorical variables are summarized as numbers and percentages
and compared between control mothers and mothers with GDM using Fisher
exact tests. Continuous variables are summarized as means and SDs or as
median and interquartile ranges and compared between control mothers and
mothers with GDM using t tests or Wilcoxon tests, as appropriate. To assess
the role of each variable in predicting GDM, logistic regression models were
ﬁtted adjusting for maternal age, BMI, gestational age at sampling, smoking,
racial group, parity, conception status, and previous GDM. HDL cholesterol,
triglycerides, and CRP were log transformed as this enhanced model ﬁt.
Forward stepwise, backward, and bootstrap variable selection (10) proce-
dures were used to identify the most important predictors. As resulted from
logistic regressions, effect estimates were reported along with 95% CIs and P
values. The predictive abilities of the different models were illustrated using
ROC curves and IDI analyses as described (11). CIs for IDI were obtained
through bootstrap based on 1,000 samples. The same analyses were repeated
in the subgroup of mothers who had not had previous GDM. All analyses have
been carried out in R, version 2.9.1 (12). P values were not adjusted for
multiple testing and were therefore considered descriptive.
RESULTS
Baseline characteristics and simple adjustments. We
identiﬁed 124 women who developed GDM and 248 con-
trol subjects. Their characteristics are provided in Table 1.
In univariate analyses, women who developed GDM were
older, had greater BMI, and more had prior GDM and
family history of type 2 diabetes. They also had higher
systolic blood pressure, but there were no relevant differ-
ences in parity, smoking history, or method of conception.
As regards biochemical measures, women destined to
develop GDM had higher total cholesterol, LDL choles-
terol, triglycerides, CRP, and t-PA but lower levels of HDL
cholesterol and adiponectin. GGT levels demonstrated a
tendency to be higher in women destined to develop GDM,
and there was no relevant difference in E-selectin. Adjust-
ment for potential confounders resulted in loss of signiﬁ-
cance for several of the above measures, most notably
systolic blood pressure, and the results were similar
whether we examined the entire group or looked at the
large subgroup of women without a history of GDM.
Stepwise variable selection in all mothers and moth-
ers without prior GDM. Given that many of the risk
factors have known strong interrelationships (e.g., triglyc-
erides, HDL cholesterol, adiponectin, and t-PA, etc.), we
examined for independent predictors using a forward
stepwise variable-selection approach (Table 2). In the
entire cohort, we noted that of the measures forced into
the model, gestational age at sampling, BMI, Asian racial
group, parity, and prior GDM were associated with GDM,
whereas of the parameters shown to be signiﬁcant in
univariate analyses but not forced into model, only family
history of diabetes, lower HDL cholesterol, and higher
t-PA remained independently predictive (Table 2). The
results were near identical when analysis was repeated in
the women without prior GDM (Table 2). The models
obtained through backward selection were identical.
Predictive ability of simple and extended prediction
models. We determined the predictive ability of simple
measures routinely available at booking visit (namely
maternal age, gestational age at sampling, BMI, race,
family history of diabetes, and prior GDM) in the entire
cohort. This demonstrated an AUC-ROC of 0.824, which
increased signiﬁcantly to 0.861 with the addition of HDL
cholesterol and t-PA (Fig. 1A). Upon repeating the same
analyses but removing all women with prior GDM, the
AUC-ROCs were 0.751 and 0.806, respectively (Fig. 1B).
As an additional prediction test, we examined for IDI in
the models, a test that is not based on a priori risk classes
and is therefore applicable in this setting. The results for
IDI are similar to those found for the AUC: adding HDL
cholesterol to the basic risk factor model improves dis-
crimination compared with the basic model (IDI 	 0.031,
95% bootstrap CI [1,000 samples] 0.000–0.092), adding
t-PA to the basic model improves discrimination slightly
more than does HDL cholesterol (0.033 [0.006–0.082]),
whereas using both variables leads to the biggest improve-
ment (0.052 [0.017–0.115]) over the basic model. Adding
t-PA to the basic model plus HDL cholesterol yields an IDI
of 0.021 (0.002–0.062), adding HDL cholesterol to the basic
model plus t-PA yields an IDI of 0.019 (0.000–0.066). So
each variable improves discrimination when added to the
basic model, and discrimination further improves if they
are both used.
Bootstrap variable selection. Applying bootstrap vari-
able selection (with the adjustment variables forced into
the model), the variables with the highest selection prob-
abilities are family history of diabetes (90.1%), t-PA
(59.8%), adiponectin (61.3%), and HDL cholesterol (50.5%).
In a joint model using all those variables, adiponectin is no
longer signiﬁcant (see the supplementary Table in the online
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content/full/db10-0688/DC1). In women without previous
GDM, the results are very similar (selection probabilities
for family history of diabetes 81.8%, for t-PA 70.3%, for
adiponectin 55.8%, and for HDL cholesterol 54.0%). Again,
adiponectin is not signiﬁcant in a joint model of all those
variables.
DISCUSSION
This study, conducted in a mixed ethnic population in a
U.K. teaching hospital, highlights some novel and poten-
tially clinically important aspects of routine and nonrou-
tine tests to predict GDM. Most importantly, our results
suggest that very good prediction of GDM, using a panel of
simple maternal demographic and clinical characteristics,
is possible, with achieved AUC-ROC values not dissimilar
to those noted for type 2 diabetes in the general population
where AUC-ROCs typically around 0.75–0.85 are reported
(1). Our work also extends the recent study by Van
Leeuwen et al. (13), in which a few maternal characteris-
tics yielded an AUC-ROC of 0.77 for GDM, although in this
study only 22 cases were recorded from 995 women
screened. Furthermore, we show that although several
novel biochemical parameters may be associated with
TABLE 1















Maternal age (years) 0/0 32.6 
 5.2 34.3 
 5.0 0.002‡ 0.430 0.420
Maternal BMI at booking (kg/m
2) 0/0 25.4 
 5.2 29.2 
 7.9 0.001§ 0.001 0.001
Parity
Nullip 0/0 89 (35.9) 45 (36.3) 1.000 0.003 0.003
Parous 159 (64.1) 79 (63.7)
Ethnicity
White 148 (59.7) 73 (58.9)
Black 0/0 62 (25.0) 34 (27.4) 0.769 0.325 0.440
Asian 29 (11.7) 11 (8.9)
Other 9 (3.6) 6 (4.8)
Previous GDM
No 158 (63.7) 44 (35.5) —
Yes 0/0 1 (0.4) 35 (28.2) 0.001 0.001
Nulliparous 89 (35.9) 45 (36.3)
Family history of diabetes
No 0/0 218 (87.9) 76 (61.3) 0.001 0.001 0.001
Yes 30 (12.1) 48 (38.7)
Smoker
No 0/0 230 (92.7) 115 (92.7) 1.000 0.605 0.593
Yes 18 (7.3) 9 (7.3)
Gestational age at booking (days) 0/0 87.4 
 3.2 87.3 
 3.6 0.737‡ 0.864 0.967
Systolic blood pressure (mmHg) 58/27 111.7 
 16.6 118.4 
 14.1 0.001§ 0.281 0.269
Diastolic blood pressure (mmHg) 58/27 71.4 
 8.9 72.9 
 8.4 0.163‡ 0.585 0.688
Mode of delivery
Vaginal 190 (77.2) 80 (65.0)
Elective caesarean section 2/1 36 (14.6) 25 (20.3) 0.037 0.438 0.503
Emergency caesarean section 19 (7.7) 18 (14.6)
Ventouse 1 (0.4) 0 (0.0)
Sex
Female 0/0 118 (47.8) 62 (50.0) 0.741 0.862 0.985
Male 129 (52.2) 62 (50.0)
Birth weight (g) 0/0 3,392.8 
 540.3 3,343.2 
 495.0 0.378‡ 0.896 0.911
Gestation at OGTT (weeks) 0 — 27.7 
 4.7
OGTT (fasting, 2-h glucose) 0, 6 — 5.3 
 1.7; 9.1 
 1.6
OGTT (A1C) (%) 14 — 5.8 
 0.8
Total cholesterol (mmol/l) 0/0 4.59 
 0.85 4.88 
 0.90 0.003‡ 0.040 0.038
HDL cholesterol (mmol/l)* 0/0 1.68 
 0.36 1.55 
 0.38 0.002‡ 0.003 0.001
LDL cholesterol (mmol/l) 0/0 2.29 
 0.71 2.59 
 0.78 0.001‡ 0.003 0.003
Triglycerides (mmol/l)* 0/0 1.23 (0.95–1.62) 1.49 (1.14–2.05) 0.001§ 0.017 0.012
Adiponectin (g/ml) 0/0 9.88 
 5.57 7.38 
 4.19 0.001§ 0.027 0.040
E-selectin (ng/ml) 0/0 31.3 (23.2–40.4) 31.3 (24.7–44.2) 0.308§ 0.867 0.827
GGT (U/l) 0/0 11.0 (9.0–16.0) 12.0 (9.8–17.0) 0.063§ 0.632 0.566
CRP (mg/l)* 0/0 3.21 (1.62–6.97) 5.77 (2.7–11.6) 0.001§ 0.030 0.024
t-PA 27/16 5.32 (4.23–6.58) 6.41 (5.19–8.27) 0.001§ 0.001 0.001
Data are means 
 SD, n (%), or median (interquartile range). Log transformed for regression analyses. *Adjusted for maternal age, BMI,
gestational age at sampling, smoking, ethnicity, parity, conception status, and previous GDM. †Women without previous GDM (nulliparous
or previous pregnancies without GDM) adjusted for maternal age, BMI, gestational age at sampling, smoking, ethnicity, parity, and conception
status. ‡t test; §Wilcoxon test; Fisher exact test.
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antigen (but not blood pressure, CRP, GGT, or adiponec-
tin) remain independently predictive in multivariate mod-
els and add predictive information beyond a simple panel
of predictors. Finally, useful prediction of GDM in women
without prior GDM also appears possible using simple
biochemical variables added to the readily attainable
maternal information. Collectively, our observations
should encourage others to test and validate similar simple
GDM prediction models in the same way risk prediction
algorithms for type 2 diabetes have been proposed for
clinical use (14).
The observation of an association of t-PA antigen with
incident GDM appears novel and concurs with work, most
recently from our group, of a strong association of t-PA
with risk for type 2 diabetes (8). t-PA is considered to
reﬂect endothelial activation, but its circulating levels
likely also reﬂect hepatic fat content (1), with reductions
in t-PA in association with weight loss (1,15) and met-
formin independent of glycemia or weight changes (16). It
should also be noted that t-PA appears to have a remark-
able strong correlation to insulin resistance in women with
and without polycystic ovarian syndrome (17). Thus, using
t-PA to predict GDM is in line with its known associations
to liver fat and insulin resistance and known responses to
mechanisms (lifestyle, metformin) that reduce diabetes
risk.
Our ﬁnding that low HDL cholesterol predicts incident
GDM, and type 2 diabetes in general, is also of interest but
not surprising considering the inverse association between
HDL cholesterol and triglycerides; a high-triglyceride and
low–HDL cholesterol pattern is apparent in women with
GDM (18). The clinical utility of this marker is further
enhanced by virtue of not being altered in nonfasting
samples (unlike triglyceride) and also the fact that HDL
cholesterol is routinely available in most hospitals.
It should be noted that although risk factors such as
blood pressure, CRP, and GGT may be higher, and adi-
ponectin lower in women destined to develop GDM, their
associations with GDM risk appear not to be independent
when set against other potential predictors, which, we
have argued, yield overlapping information in type 2
diabetes (1). Likewise, others have reported that adiponec-
tin may not be independently associated with GDM (19),
and our CRP results are consistent with recent data (6)
regarding the limited independent predictive value of CRP
for incident type 2 diabetes.
The potential clinical signiﬁcance of our ﬁndings relates
to the increasing importance attributed to maternal dysg-
lycemia enhancing the risk for related pregnancy compli-
TABLE 2
Regression models obtained from variable selection (forward stepwise selection) using variables that were signiﬁcant in Table 1, with
adjustment variables forced into the model
All mothers Effect 95% CI P
Variables forced in
Intercept 2.180 (6.042 to 1.683) 0.267
Age 0.017 (0.056 to 0.090) 0.648
BMI 0.127 (0.072–0.181) 0.001
Gestational age at sampling 0.085 (0.163 to 0.006) 0.034
Smoking 0.165 (1.695 to 1.365) 0.832
Ethnicity
Black 0.146 (0.956 to 0.664) 0.722
Asian 1.847 (3.310 to 0.385) 0.013
Other 1.256 (0.409 to 2.920) 0.138
Parity (parous) 1.367 (2.148 to 0.585) 0.001
Conception (spontaneous) 0.459 (1.908 to 0.990) 0.533
Previous GDM 4.477 (2.221–6.733) 0.001
Variables selected
Family history of diabetes 1.196 (0.382–2.011) 0.004
HDL cholesterol* 1.959 (3.546 to 0.372) 0.015
t-PA 0.195 (0.042–0.349) 0.012
Mothers without prior GDM
Variables forced in
Intercept 2.383 (6.345 to 1.579) 0.236
Age 0.017 (0.057 to 0.091) 0.650
BMI 0.128 (0.072–0.184) 0.001
Gestational age at sampling 0.079 (0.160 to 0.002) 0.055
Smoking 0.148 (1.697 to 1.402) 0.851
Ethnicity
Black 0.161 (0.990 to 0.668) 0.701
Asian 1.675 (3.129 to 0.222) 0.023
Other 1.306 (0.364 to 2.976) 0.124
Parity (parous) 1.385 (2.176 to 0.594) 0.001
Conception (spontaneous) 0.496 (1.961 to 0.969) 0.505
Variables selected
Family history of diabetes 1.160 (0.326–1.994) 0.006
HDL cholesterol 2.196 (3.821 to 0.572) 0.008
t-PA 0.219 (0.063 to 0.374) 0.006
Conducted in all mothers and separately in mothers without prior GDM. *Log transformed.
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hyperinsulinaemia) (20). Rising levels of obesity and re-
cent proposed changes to GDM diagnostic criteria (includ-
ing reducing fasting blood glucose levels to 5.1 mmol/l)
mean that the incidence of GDM may rise substantially
(21). The possibility, therefore, of ﬁrst-trimester identiﬁ-
cation of women at greatest risk of GDM, with subsequent
implementation of possible lifestyle or medical interven-
tions at this stage, requires further study (22). Of course,
ongoing studies will help determine whether such inter-
ventions lead to measurable clinical beneﬁts, but, never-
theless, the possibility of early screening is advanced by
our data.
Our work has a number of strengths. We measured a
range of clinical and novel predictors of GDM simulta-
neously rather than one or two novel measures in isola-
tion. As a result, our data give a better overall reﬂection of
predictive abilities, or lack thereof, for speciﬁc factors of
relevance. The size of our study was relatively large, set
against other such studies in the literature, and sufﬁciently
powered to detect associations. Finally, we were very
careful in statistical analyses and considered relevant
multivariate and stepwise models for consistency of ﬁnd-
ings, as well as two relevant prediction metrics. We
acknowledge a number of limitations. We did not have
fasting samples at baseline, but, of course, fasting is not
mandated for booking clinical visits in pregnancy. Diagno-
sis of GDM was based on current National Institute for
Health and Clinical Excellence–based criteria but with a
lower random glucose cut off but did not use the recently
proposed new criteria (21). As a result, many control
subjects did not have an OGTT, but this omission would
potentially bias results toward the null and not the other
way. Furthermore, becuase all factors identiﬁed in our
analyses relate to glucose elevations in a generally contin-
uous fashion, our data are likely applicable to any future
changes to criteria. Moreover, the mean fasting blood
glucose in subsequent GDM cases was 5.3 mmol/l, which is
above the suggested new fasting blood glucose cut off of
5.1 mmol/l, so our results appear broadly applicable to the
new criteria. Finally, we acknowledge the lack of detailed
validation of our models in other cohorts, but our aim was
not to deﬁne the best model (nor to currently consider
cost-effectiveness issues) but rather to be hypothesis
generating and to prompt others to advance our ﬁndings
toward possible clinical utility.
In conclusion, we have shown that risk for GDM can be
usefully estimated in the ﬁrst trimester of pregnancy from
a mix of simple maternal demographic and clinical char-
acteristics with potential for further improvement by
simple and novel biochemical markers. Our results sug-
gest further development, and potential clinical applica-
tion of risk algorithms for GDM in a range of populations,
is possible. Such work should therefore be prioritized,
especially at a time of rising obesity levels and changing
diagnostic criteria for GDM, factors which in combination
will substantially increase the number of women with this
condition.
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FIG. 1. A: ROC curves and summaries for all mothers using a basic
model (including age, gestational age at sampling, BMI, ethnicity,
family history of diabetes, and prior GDM) and with addition of
independent predictors (HDL cholesterol and t-PA). AUC, area under
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GDM using a basic model (including age, gestational age at sampling,
BMI, ethnicity, and family history of diabetes) and with addition of
independent predictors (HDL cholesterol and t-PA).
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